Search

Your search keyword '"Schettini F"' showing total 642 results

Search Constraints

Start Over You searched for: Author "Schettini F" Remove constraint Author: "Schettini F"
642 results on '"Schettini F"'

Search Results

1. Glycated Albumin for Glycemic Control in T2DM Population: A Multi-Dimensional Evaluation

2. Advanced Medical Devices for Preparation and Administration of Chemotherapeutic Agents: Results from a Multi-Dimensional Evaluation

3. Comparison of “IN-REC-SUR-E” and LISA in preterm neonates with respiratory distress syndrome: a randomized controlled trial (IN-REC-LISA trial)

4. Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancer

8. T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study

10. RWD101 Intravitreal Therapies and Their Patterns of Use in Lombardy Region

12. 35P SNPs of aromatase gene (CYP19A1) and outcomes of patients with estrogen receptor-positive (ER+) early breast cancer (eBC) treated with aromatase inhibitors (AIs): A multicenter, prospective study

13. 55P Clinicopathological and molecular changes induced by neoadjuvant therapy (NAT) in hormone receptor-positive (HR+)/HER2-low vs HER2 0 breast cancer (BC)

14. 208P Clinical characteristics and prognostic factors in patients with breast cancer and leptomeningeal metastases: A subanalysis of the German brain metastases in breast cancer registry (BMBC)

15. P317 A…TELL–TALE HEART

16. 8P First decision impact study of HER2DX in patients (pts) with HER2-positive (HER2+) early breast cancer

17. 10P HER2 loss and PAM50 dynamics after neoadjuvant therapy (NAT) in HER2-positive (HER2+) early breast cancer (BC)

18. Embedding the Patient-Citizen Perspective into an Operational Framework for the Development and the Introduction of New Technologies in Rehabilitation Care: The Smart&Touch-ID Model

22. 357P Bridging the gap between real-world studies (RWSs) and randomized controlled trials (RCTs) of 1st-line palbociclib+aromatase inhibitors (P+AI) in hormone receptor-positive (HR+)/HER2-negative(-) metastatic breast cancer (mBC).

23. 125P Assessing the accuracy of multiple prognostic scores for immune checkpoint inhibitors (ICI) in patients with advanced solid tumors

24. 263P Clinical outcomes in patients with germline pathogenic variants in homologous recombination repair (HRR) genes treated with CDK4/6 inhibitors (CDK4/6i) and endocrine therapy (ET)

25. Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer

26. 3MO Association of the research-based HER2DX signatures with survival in early-stage triple-negative breast cancer (eTNBC)

27. Pazienti diabetici di tipo 2, non in terapia insulinica e albumina glicata: UNA valutazione multidimensionale [Insuline-Naive type 2 diabetic patients: a multidimensional evaluation on the role of glycated albumin]

34. C9 - A propensity score analysis exploring the impact of adjuvant chemotherapy (aCT) in 739 patients (pts) affected by early stage pure Invasive Lobular breast Carcinoma (ILC)

37. Pazienti diabetici di tipo 2, non in terapia insulinica e albumina glicata: UNA valutazione multidimensionale [Insuline-Naive type 2 diabetic patients: a multidimensional evaluation on the role of glycated albumin]

38. 81P Baseline circulating CD4+PD1+high T cells (TCD4PD1H) as predictors of survival in patients (P) with solid tumors treated with immune-checkpoint inhibitors (ICI)

39. 275P Clinical and molecular impact of neoadjuvant chemotherapy (NACT) or endocrine therapy (NET) on hormone receptor positive (HR+)/HER2-negative (-) breast cancer (BC)

40. BRAF Signaling Inhibition in Glioblastoma: Which Clinical Perspectives?

41. Endocrine‐based treatments in clinically‐relevant subgroups of hormone receptor‐positive/her2‐negative metastatic breast cancer: Systematic review and meta‐analysis

42. Anthracyclines strike back: Rediscovering non‐pegylated liposomal doxorubicin in current therapeutic scenarios of breast cancer

43. Glycated Albumin for Glycemic Control in T2DM Population: A Multi-Dimensional Evaluation

44. Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy: ER activity in pre-menopausal HR+ breast cancer during CT

46. 109P Subsequent therapies after progressing to CDK4/6 inhibition (CDK4/6i) in hormone receptor positive/HER2 negative (HR+/HER2-) advanced breast cancer (ABC)

47. 23P CDK4/6 inhibition and endocrine therapy (ET) in the HER2-enriched subtype (HER2-E) in hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer (ABC): A retrospective analysis of real-world data

48. PMD164 - THE MANAGEMENT OF GLYCAEMIC CONTROL IN DIABETIC PATIENTS (T2): THE ROLE OF GLYCATED ALBUMIN

49. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

50. Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis

Catalog

Books, media, physical & digital resources